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HoBACKGROUND Loss-of-function mutations in the SGLT1 (sodium/glucose co-transporter-1) gene result in a rare
glucose/galactose malabsorption disorder and neonatal death if untreated. In the general population, variants related to
intestinal glucose absorption remain uncharacterized.
OBJECTIVES The goal of this study was to identify functional SGLT1 gene variants and characterize their clinical
consequences.
METHODS Whole exome sequencing was performed in the ARIC (Atherosclerosis Risk in Communities) study partici-
pants enrolled from 4 U.S. communities. The association of functional, nonsynonymous substitutions in SGLT1 with 2-h
oral glucose tolerance test results was determined. Variants related to impaired glucose tolerance were studied, and
Mendelian randomization analysis of cardiometabolic outcomes was performed.
RESULTS Among 5,687 European-American subjects (mean age 54  6 years; 47% male), those who carried a haplo-
type of 3 missense mutations (frequency of 6.7%)—Asn51Ser, Ala411Thr, and His615Gln—had lower 2-h glucose and odds
of impaired glucose tolerance than noncarriers (b-coefficient: 8.0; 95% confidence interval [CI]: 12.7 to 3.3; OR:
0.71; 95% CI: 0.59 to 0.86, respectively). The association of the haplotype with oral glucose tolerance test results was
consistent in a replication sample of 2,791 African-American subjects (b ¼ 16.3; 95% CI: 36.6 to 4.1; OR: 0.39; 95% CI:
0.17 to 0.91) and an external European-Finnish population sample of 6,784 subjects (b ¼ 3.2; 95% CI: 6.4 to 0.02;
OR: 0.81; 95% CI: 0.68 to 0.98). Using a Mendelian randomization approach in the index cohort, the estimated 25-year
effect of a reduction of 20 mg/dl in 2-h glucose via SGLT1 inhibition would be reduced prevalent obesity (OR: 0.43; 95%
CI: 0.23 to 0.63), incident diabetes (hazard ratio [HR]: 0.58; 95% CI: 0.35 to 0.81), heart failure (HR: 0.53; 95% CI: 0.24
to 0.83), and death (HR: 0.66; 95% CI: 0.42 to 0.90).
CONCLUSIONS Functionally damaging missense variants in SGLT1 protect from diet-induced hyperglycemia in multiple
populations. Reduced intestinal glucose uptake may protect from long-term cardiometabolic outcomes, providing sup-
port for therapies that target SGLT1 function to prevent and treat metabolic conditions. (J Am Coll Cardiol 2018;72:1763–73)
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1764A fter ingestion, complex carbohy-drates are enzymatically brokendown to produce monosaccharides
(glucose, galactose, and fructose), which are
absorbed in the small intestine and used as
substrate for the body’s metabolically active
tissues. The sodium/glucose co-transporter
(SGLT)-1 protein is a rate-limiting factor for
absorption of glucose and galactose in the
small intestine, and it uses transmembrane
sodium gradients to drive the cellular uptake
of these molecules. Loss-of-function muta-
tions, including missense, nonsense, and
frameshift mutations, of the SGLT1 gene
result in impaired cellular glucose transport
and cause glucose-galactose malabsorption
(GGM). GGM is a rare, autosomal recessive,
Mendelian disorder resulting in neonatal
onset of severe diarrhea, dehydration, and
malabsorption (1–3).SEE PAGE 1774Functional gene variants in SGLT1 associ-
ated with altered glucose metabolism in the
general population have not been described.
However, in the process of identifying causal
mutations for GGM, SGLT1 gene variants thatare associated with subtle abnormalities of glucose
absorption in vivo have been identified; the impor-
tance of these variants, which do not result in GGM, is
unknown (1). We hypothesized that rare or low-
frequency variants in SGLT1 that are predicted to be
damaging, but still preserve some of the protein’s
function, result in lower postprandial blood glucose
levels by decreasing glucose uptake in the smallHHSN268201100005C, HHSN268201100006C, HHSN26820110000
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tion. Rare or low-frequency variant analysis of SGLT1
has not been systematically studied in the general
population and could provide insights into the gene’s
relationship with diet and disease, as well as potential
drug targets for hyperglycemia and obesity and its
consequences. We assessed the relationship between
protein-altering, nonsynonymous (NS) substitutions
in SGLT1 and glycemia and obesity by using whole
exome sequencing performed in participants from 4
U.S. communities who were enrolled in the ARIC
(Atherosclerosis Risk In Communities) study.
External validation was then performed in a
European-Finnish population sample (FINRISK and
DILGOM [Dietary, Lifestyle and Genetic Predictors of
Obesity and Metabolic Syndrome] study). A Mende-
lian randomization approach was then used to esti-
mate the effect of SGLT1 inhibition on long-term
cardiometabolic outcomes.
METHODS
STUDY DESIGN AND STUDY POPULATION. Originally
comprising 15,792 men and women aged between 45
and 64 years, the ARIC study is an ongoing, pro-
spective observational trial of atherosclerosis risk
factors in 4 U.S. communities (Forsyth County, North
Carolina; Jackson, Mississippi; suburbs of Minneap-
olis, Minnesota; and Washington County, Maryland)
recruited between 1987 and 1989 (visit 1) (4). ARIC
study participants were initially examined every 3
years, with the second examination occurring in the
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1765approved the study protocol. Informed consent was
obtained in writing at each study visit. Participants
were excluded from this analysis if they restricted use
of their deoxyribonucleic acid (DNA) (n ¼ 44).
MEASUREMENT OF DIET. At the baseline visit (1987
to 1989), participants were interviewed by using a
66-item semi-quantitative food frequency question-
naire (FFQ), modified from a 61-item validated FFQ
(5). Participants reported the occurrence with which
they consumed individual foods or beverages in 9
categories (ranging from never or <1 time per month
to $6 times per day). Nutrient intakes were derived
from FFQ responses using the Harvard Nutrient
Database.
PHENOTYPIC MEASUREMENTS. Age, sex, race (self-
reported), total cholesterol (measured by using blood
plasma assay), high-density lipoprotein (measured
by blood plasma assay), current smoking status
(self-reported), hypertension (HTN) (defined
as þantihypertensive medications or blood pressure
>140/90 mm Hg), estimated glomerular filtration
rate, chronic kidney disease (defined as an estimated
glomerular filtration rate <60 ml/min/1.73 m2), and
obesity (defined as a body mass index $30 kg/m2)
were analyzed at baseline visit. Baseline systolic
blood pressure was adjusted for þ15 mm Hg and
diastolic blood pressure þ10 mm Hg if the subject was
taking antihypertensive medication (assessed by self-
reported questionnaire). A standard 75-g oral glucose
tolerance test (OGTT) was performed after an over-
night fast before ARIC visit 4 (1996 to 1998). Partici-
pants who were taking diabetes mellitus (DM)
medications at visit 4, had a recent history of taking
DM medications (at visit 3), reported not fasting for at
least 12 h, or had had part of their stomach removed
did not qualify to undergo OGTT. Impaired glucose
tolerance (IGT) was defined as a 2-h postprandial
glucose level $140 mg/dl to associate all individuals
with potentially abnormal physiological handling of
glucose to gene variants of interest. All participants
who underwent OGTT were included in the current
analysis.
Sensitivity analyses were performed excluding in-
dividuals with a diagnosis of DM or with a fasting
plasma glucose level >126 mg/dl. All analytes were
determined at central laboratories according to stan-
dard protocols. Plasma glucose was measured by us-
ing a hexokinase assay.
OUTCOMES. Outcomes evaluated in this study are
incident DM diagnosis, initiation of DM medications,
death, and incident heart failure (HF), from the first
visit until 2015 (median 25-year follow-up). Because
heritable functional variations in SGLT1 couldtheoretically influence an individual’s success in the
dietary management of DM, a diagnosis of DM and
initiation of DM medications were explored sepa-
rately as outcomes. Patients at risk of HF are also at
risk of cardiovascular death before development of
overt HF; thus, both the individual outcomes as well
as a composite of the first occurrence of HF or death
was assessed. The methods used for the detection
and adjudication of events have been presented pre-
viously (6–8). Incident death was determined via
death certificates, hospitalized patients, physician
questionnaires, and next-of-kin interviews. Incident
HF was defined as the first HF hospitalization iden-
tified by International Statistical Classification of
Diseases and Related Health Problems (ICD) codes
428 (for ICD-9) or I50 (for ICD-10) in any position on
hospital discharge or deaths coded as HF (428 or I50)
in any position on death certificates (8). Incident
cases of DM were identified based on self-reported
DM diagnosis or use of DM medications during the
scheduled ARIC visits as well as annual telephone
interviews conducted with participants for a
maximum of 15 years of follow-up (7).
WHOLE EXOME SEQUENCING. Whole exome
sequencing was performed at the Baylor College of
Medicine Human Genome Sequencing Center (HGSC),
using the HGSC VCRome 2.1 reagent (9) (42 Mb, Nim-
bleGen). All samples underwent paired-end
sequencing by using GAII or HiSeq instruments (Illu-
mina, San Diego, California). Atlas2 suite was used to
perform the variant calling (10). The DNA sampleswere
constructed into Illumina paired-end pre-capture
libraries according to the manufacturer’s protocol.
The complete protocol and oligonucleotide sequences
are accessible from the Baylor College of Medicine–
HGSC website. Barcoded pre-capture libraries were
pooled and then hybridized to NimbleGen exome
capture array (HGSC VCRome 2.1 design [9]) (42 Mb,
NimbleGen) and sequenced in paired-end mode in a
single lane on the Illumina HiSeq 2000 platform. Illu-
mina sequence analysis was performed by using the
HGSC Mercury analysis pipeline. Pooled samples were
de-multiplexed by using Consensus Assessment of
Sequence and Variation software (Illumina). Reads
were then mapped to the Genome Reference Con-
sortium Human Build 37 human reference sequence
using Burrows-Wheeler Aligner (11) producing binary
alignment/map files. Aligned reads were then recali-
brated by using the Genome Analysis Toolkit (12) along
with binary alignment/map sorting, duplicate read
marking, and realignment near insertions or deletions.
The Atlas2 (10) suite was used to call variants and
produce high-quality variant call files (13).
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based on the following criteria to produce a high-
quality variant list: low single nucleotide variant
posterior probability (<0.95), low variant read count
(<3), variant read ratio <0.25 or >0.75, strand-bias of
>99% variant reads in a single strand direction,
or total coverage <10-fold. All variant calls filtered
according to these criteria, and reference calls with
<10-fold coverage, were set to missing. The variant
call filters were the same for insertions or deletions
except a total coverage <30-fold was used. Variant-
level quality control steps excluded variants outside
the exon capture regions (VChrome 2.1), multi-allelic
sites, missing rate >20%, and mean depth of
coverage >500-fold. Variants not meeting Hardy-
Weinberg equilibrium expectations in ancestry-
specific groups (p < 5  106) were also excluded.
Sample-level quality control metrics were calculated
according to cohort and ancestry group. A sample was
excluded for missingness >20%, or, if compared with
the other samples, it fell <6 SDs for mean depth,
>6 SDs for singleton count, or outside of 6 SDs for
heterozygote to homozygote ratio or a transition-to-
transversion ratio. We selected all NS variants in the
SGLT1 gene for this study. Protein function was
determined from previous in vivo studies of heterol-
ogous expression that determined glucose uptake in
cells expressing SGLT1 mutant proteins (1).
EXTERNAL VALIDATION COHORTS. FINRISK is a
series of cardiovascular risk factor surveys conducted
in Finland every 5 years since 1972 (14). DNA has been
collected since the 1992 survey. The FINRISK 2002
study is a stratified, random sample of the population
25 to 74 years of age from 6 geographical areas of
Finland (15). The original population sample was
13,500, and the overall participation rate was 65.5%
(n ¼ 8,798). Participation included a questionnaire
and health examination in which blood samples were
drawn. Testing for OGTT with fasting and 2-h glucose
assessment was conducted in a separate session for
participants 45 to 74 years of age (n ¼ 3,738)
approximately 2 months after the baseline survey.
The DILGOM study is an extension of the FINRISK
2007 survey and is based on an independent popu-
lation sample, separate from FINRISK 2002 (16). All
participants of FINRISK 2007 were further invited to
take part in a more detailed study (i.e., DILGOM). The
participation rate was 80% (n ¼ 5,024). The baseline
examination of DILGOM in 2007 was conducted about
3 months after the original FINRISK 2007 survey. It
included a 2-h OGTT with measurements of fasting
and 2-h glucose assessment.Of the FINRISK and DILGOM participants with
OGTT, a total of 6,784 had data on IGT and 2-h
glucose assessments available for the present anal-
ysis. The analysis on prevalent obesity included
FINRISK-92, -97, -02, -07, and -12 cohorts (total
N ¼ 27,294). All analyses were performed by using
directly genotyped or 1,000 Genomes phase 3
imputed data (quality >0.99).
STATISTICAL ANALYSIS. Baseline characteristics are
reported by using descriptive statistics for continuous
variables and number counts and percentages for
categorical variables. Linear regression and chi-
square tests for trend were used to test for a rela-
tionship between continuous or categorical baseline
variables, respectively, and SGLT1 genotype. All an-
alyses were adjusted for age at the time that the
measurement was obtained, sex, and, in a combined
analysis, the first 10 principal components from
EIGENSTRAT (17) to minimize confounding by
ancestry. Genotype–phenotype associations were first
examined in a sample of European-American subjects
with exome sequencing genotypes and then repli-
cated in African-American subjects. To estimate the
contribution of an individual missense mutation to
the overall NS variant signal, conditional analyses
were performed. These evaluated the association of
all NS variants with IGT, further adjusting for each
individual missense mutation as a covariate. Survival
analysis methods were used for the following out-
comes: diagnosis of DM, initiation of DM medications,
death, and HF. Follow-up time was calculated as the
time from the first examination to the time of the first
event or the last known date of follow-up (up to
December 31, 2014).
Kaplan-Meier failure curves were created for each
outcome, and hazard ratios (HRs) were calculated by
using Cox proportional hazards regression. These
analyses were first tested in an unadjusted model and
then adjusted for age, sex, and the first 10 principal
components from EIGENSTRAT (17) to minimize
confounding by ancestry. The causal effects of
reduced 2-h glucose values on outcomes and quanti-
tative traits were examined according to conventional
Mendelian randomization (2-stage least-squares
estimator method), which uses predicted values of
2-h glucose per genotype and regresses each outcome
or trait against these predicted values. Models were
tested for each outcome variable and were adjusted
for age, sex, and the first 10 principal components. All
data were analyzed by using STATA version 14.0
(StataCorp, College Station, Texas). Values of p < 0.05
were considered statistically significant.
TABLE 1 Baseline Characteristics of European-American and African-American Participants in the ARIC Cohort Stratified According to the
Presence of 1 or $2 NS Substitutions in SGLT1

















Patients 4,772 (84) 105 (2) 810 (14) 2,583 (92.5) 124 (4.5) 84 (3)
Age, yrs 54  6 54  6 54  6 0.83 53  6 54  6 54  6 0.03
Male 2,268 (48) 44 (42) 385 (48) 0.88 933 (36) 46 (37) 30 (36) 0.97
Smoking 1,174 (25) 18 (17) 187 (23) 0.25 724 (28) 41 (33) 28 (33) 0.13
Current EtOH 3,262 (68) 80 (76) 561 (69) 0.44 794 (31) 45 (37) 30 (36) 0.15
TC, mg/dl 215  39 216  35 215  38 0.95 213  41 215  51 214  39 0.52
HDL, mg/dl 51  17 54  18 51  17 0.42 55  18 54  17 56  18 0.97
LDL, mg/dl 137  36 138  33 138  35 0.71 136  38 138  46 137  36 0.58
Triglycerides, mg/dl 139  98 129  118 132  87 0.07 112  85 116  61 115  67 0.59
SBP, mm Hg 122.1  19.0 120.7  18.3 120.8  18.7 0.06 133.4  21.2 133.7  23.1 135.7  25.8 0.37
DBP, mm Hg 74.2  11.3 73.8  10.8 73.3  11.1 0.028 83.6  12.9 84.2  15.6 81.3  15.1 0.29
Antihypertensive medication 1,200 (25) 45 (26) 156 (21) 0.029 1,080 (42) 52 (42) 41 (49) 0.23
HTN 1,262 (26) 46 (27) 164 (22) 0.021 1,363 (53) 68 (55) 47 (56) 0.45
Uric acid, mg/dl 5.17  1.52 5.11  1.60 4.96  1.39 <0.001 5.43  1.63 5.73  1.67 5.47  2.07 0.26
eGFR 89.3  17.9 88.5  18.6 88.9  16.6 0.46 103.4  26.4 101.8  25.2 109.9  29.5 0.13
CKD 145 (3.0) 4 (2.3) 16 (2.2) 0.17 55 (2.2) 4 (3.3) 0 (0.0) 0.47
Heart rate, beats/min 66.5  10.0 64.9  9.9 65.5  9.4 0.005 66.8  10.8 67.6  12.1 65.1  10.1 0.43
Total energy intake, kcal 1,644  602 1,553  498 1,623  597 0.28 1,580  614 1,696  642 1,515  568 0.85
Sodium intake, mg 1,513  601 1,529  611 1,553  639 0.08 1,354  544 1,428  536 1,303  571 0.99
Sucrose intake, g 51  36 43  25 49  33 0.05 58  37 65  45 58  37 0.30
Glucose intake, g 22  14 20  11 22  14 0.63 24  16 27  17 24  13 0.65
Fructose intake, g 24  17 21  12 24  16 1.00 27  18 30  21 26  16 0.72
Lactose intake, g 14  13 14  11 16  14 0.04 10  10 9  8 9  8 0.41
Values are n (%) or mean  SD.
ARIC ¼ Atherosclerosis Risk In Communities Study; CKD ¼ chronic kidney disease (defined as estimated glomerular filtration rate <60 ml/min/1.73 m2); DBP ¼ diastolic blood
pressure (adjusted for the use of antihypertensive medication); eGFR ¼ estimated glomerular filtration rate; EtOH ¼ alcohol; HDL ¼ high-density lipoprotein cholesterol;
HTN ¼ hypertension (defined as þantihypertensive medications or blood pressure >140/90 mm Hg); LDL ¼ low-density lipoprotein cholesterol; NS ¼ nonsynonymous;
SBP ¼ systolic blood pressure (adjusted for the use of antihypertensive medication); SGLT1 ¼ sodium/glucose co-transporter-1; TC ¼ total cholesterol.
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Whole exome sequencing was performed in 8,478
participants in the ARIC cohort; 5,687 were European
American and 2,791 were African American. A total of
915 (16%) European-American subjects and 208 (7.5%)
African-American subjects carried at least 1 NS sub-
stitution in SGLT1 (Table 1, Online Table 1). Overall,
baseline characteristics of the study population were
similar between those who carried at least 1 NS sub-
stitution and those who did not. However, in
European-American subjects, diastolic blood pres-
sure, use of antihypertensive medications, prevalent
HTN, uric acid levels, and heart rate were lower in
those who carried at least 1 NS substitution in SGLT1.
The mean number of NS substitutions in European-
American and African-American subjects was 0.4
and 0.1, respectively.
We first tested whether overall NS variants were
associated with phenotypes most likely to be corre-
lated with SGLT1 function in ARIC European-
American subjects, given its larger size. Carryingone or more copies of an NS variant was associated
with lower fasting and postprandial plasma glucose
levels, lower risk of IGT, and obesity in European-
American subjects (Online Table 2). Next, to identify
specific NS variants that may have contributed to the
overall NS substitution results, we tested the rela-
tionship of individual variants with IGT, which was
the strongest detected association. All participants
who underwent OGTT were included to study
potentially abnormal physiological handling of
glucose in SGLT1 variants. Sensitivity analyses
excluding individuals with a DM diagnosis or those
with fasting plasma glucose levels >126 mg/dl yielded
similar results. Three variants (N51S, A411T, and
H615Q) were significantly associated with a 25% to
27% reduction in IGT (odds ratio [OR]: 0.73, 0.72, and
0.75, respectively) (Central Illustration, Table 2). These
variants were in high linkage disequilibrium,
comprising a risk haplotype with a minor allele fre-
quency of 6.7% (Online Table 3). Conditional
analysis showed that the association of NS sub-
stitutions with IGT was completely explained by the
CENTRAL ILLUSTRATION Phenotype of Participants in the ARIC Study Cohort According to SGLT1 Asn51Ser/
Ala411Thr/His615Gln Haplotype Carrier Status
Seidelmann, S.B. et al. J Am Coll Cardiol. 2018;72(15):1763–73.
Whole exome sequencing of Sglt1 was performed in ARIC (Atherosclerosis Risk in Communities) study participants enrolled from 4 U.S. communities. Among 5,687
European-American subjects (mean age 54  6 years), those who carried a haplotype of 3 missense mutations (Asn51Ser, Ala411Thr, and His615Gln) had lower 2-h
glucose and odds of impaired glucose tolerance than noncarriers. The association of the haplotype with oral glucose tolerance test results was consistent in a
replication sample of 2,791 African-American subjects and an external European-Finnish population sample of 6,784. Using a Mendelian randomization approach in
the index cohort, we estimated the 25-year effect of a 20 mg/dl reduction in 2-h glucose via sodium/glucose cotransporter-1 (SGLT1) inhibition on prevalent obesity,
incident diabetes, heart failure, and death. DILGOM ¼ Dietary, Lifestyle and Genetic Predictors of Obesity and Metabolic Syndrome.
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TABLE 2 List of NS Variants From Exome Sequencing of SGLT1 in ARIC European-American and African-American Subjects
Allele











With IGT* OR (95% CI)
Conditional
Analysis†
European-American subjects (n ¼ 5,687)
834 22 32506050 rs33954001 C G p.His615Gln c.1845C>G 0.74 11.22 0.75 (0.63–0.90) 0.69 (0.52–0.93)
829 22 32445946 rs17683011 A G p.Asn51Ser c.152A>G 1.23 14.55 0.73 (0.61–0.87) 0.81 (0.59–1.11)
773 22 32487700 rs17683430 G A p.Ala411Thr c.1231G>A 2.94 22.80 0.72 (0.60–0.87) 0.77 (0.54–1.09)
23 22 32479102 rs150117594 G T p.Val209Leu c.625G>T 0.76 11.39 1.00 (0.38–2.62) 0.83 (0.75–0.92)
19 22 32506051 rs61733910 G A p.Gly616Ser c.1846G>A 1.14 13.97 1.07 (0.38–3.08) 0.83 (0.75–0.92)
10 22 32439318 rs33951240 T C p.Val17Ala c.50T>C 0.17 5.82 1.00 (0.17–6.04) 0.83 (0.75–0.92)
7 22 32439303 rs150288967 C T p.Ala12Val c.35C>T 0.41 8.63 1.57 (0.31–7.96) 0.83 (0.75–0.92)
4 22 32505988 rs147453689 C A p.Pro595Thr c.1783C>A 0.80 11.66 4.78 (0.49–46.3) 0.83 (0.75–0.92)
3 22 32439369 rs139760182 T C p.Ile34Thr c.101T>C
3 22 32482251 rs141412905 G A p.Gly356Ser c.1066G>A
2 22 32439357 . C T p.Ser30Phe c.89C>T
2 22 32479100 . C T p.Thr208Met c.623C>T
2 22 32480470 . A C p.Met237Leu c.709A>C
2 22 32481013 . C G p.Leu338Val c.1012C>G
2 22 32500780 . G A p.Arg558His c.1673G>A
African-American subjects (n ¼ 2,791)
110 22 32439318 rs33951240 T C p.Val17Ala c.50T>C 0.17 5.82 1.24 (0.62–2.50) 0.62 (0.41–0.95)
84 22 32445946 rs17683011 A G p.Asn51Ser c.152A>G 1.23 14.55 0.39 (0.17–0.91) 1.13 (0.58–2.17)
82 22 32487700 rs17683430 G A p.Ala411Thr c.1231G>A 2.94 22.8 0.39 (0.17–0.91) 1.13 (0.58–2.17)
82 22 32506050 rs33954001 C G p.His615Gln c.1845C>G 0.74 11.22 0.40 (0.17–0.91) 1.13 (0.59–2.18)
5 22 32506051 rs61733910 G A p.Gly616Ser c.1846G>A 1.14 13.97 0 0.73 (0.52–1.04)
2 22 32439338 rs201800716 C T p.Arg24Cys 1.64 16.68
24 additional variants in European-American subjects and 15 additional variants in African-American subjects only represented in a single individual are not listed. *Adjusted for age and sex. †Conditional
analysis tests the association of all NS variants with impaired glucose tolerance (IGT) on oral glucose tolerance test adjusting for each individual mutation as a covariate. This estimates the contribution of the
individual mutation in the overall NS signal. IGT was defined as 2-h glucose level $140 mg/dl.
Alt ¼ alternate nucleic acid; CADD ¼ Combined Annotation Dependent Depletion; Chrom ¼ chromosome; CI ¼ confidence interval; OR ¼ odds ratio; Ref ¼ reference nucleic acid; other abbreviations as in
Table 1.
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1769N51S/A411T/H615Q haplotype, suggesting that this
haplotype was responsible for the original NS signal.
Complete characterization of the N51S/A411T/H615Q
haplotype in ARIC European-American subjects
revealed a significant association with lower levels of
postprandial glucose (b ¼ 8.0; 95% confidence in-
terval [CI]: 12.7 to 3.3), risk for IGT (OR: 0.71;
95% CI: 0.59 to 0.86), and prevalent obesity (OR: 0.79;
95% CI: 0.66 to 0.96) (Table 3). To further validate our
primary findings, we examined the associations with
OGTT phenotypes in an independent sample of in-
dividuals of European ancestry living in Finland and
participating in the FINRISK and DILGOM studies
(mean age 54  12 years; body mass index 27.4 
4.8 kg/m2; 47% male). The SGLT1 haplotype (minor
allele frequency of 5.6%) was significantly associated
with lower 2-h glucose values (b ¼ 3.2; 95% CI: 6.4
to 0.02) and IGT (OR: 0.80; 95% CI: 0.74 to 0.91), and
displayed a directionally consistent relationship with
obesity in this sample.
We further tested the association of the N51S/
A411T/H615Q haplotype with OGTT and obesity in
ARIC African-American subjects (minor allelefrequency of 1.5%) (Online Table 3). The haplotype
was significantly associated with lower risk of IGT
(OR: 0.39; 95% CI: 0.17 to 0.91) and obesity (OR: 0.60;
95% CI: 0.37 to 0.98) and a trend for 2-h glucose
values (b ¼ 16.3; 95% CI: 36.6 to 4.1) in that pop-
ulation (Central Illustration, Table 3). A combined
analysis included ARIC European-American subjects,
ARIC African-American subjects, and FINRISK/DIL-
GOM European Finnish subjects with additional
adjustment for principal components as covariates to
minimize confounding by ancestry. The N51S/A411T/
H615Q haplotype was significantly associated with
2-h glucose levels (b ¼ 4.9; 95% CI: 7.5 to 2.3;
p ¼ 2.4  104), lower risk for IGT (OR: 0.75; 95% CI:
0.66 to 0.85; p ¼ 1.1  105) as well as prevalent
obesity (OR: 0.80; 95% CI: 0.70 to 0.93; p ¼ 2.5  103)
without a significant effect on fasting plasma glucose
values (Table 3). The association of IGT and haplo-
type remained significant after including obesity as a
covariate in the ARIC populations (OR: 0.74; 95% CI:
0.61 to 0.90).
To test the association of the N51S/A411T/H615Q
haplotype with disease phenotypes that may be
TABLE 3 OGTT Results and Prevalent Obesity in Participants in the ARIC and FINRISK/DILGOM Cohorts Stratified According to the










European-American subjects (n ¼ 5,687) 2.7 (5.1 to0.3) 8.0 (12.7 to 3.3) 0.71 (0.59 to 0.86) 0.79 (0.66 to 0.96)
p value* 0.16 9.4  104 3.2  104 0.017
African-American subjects (n ¼ 2,791) 4.3 (19.7 to 11.1) 16.3 (36.6 to 4.1) 0.39 (0.17 to 0.91) 0.60 (0.37 to 0.98)
p value* 0.58 0.12 0.03 0.040
FINRISK/DILGOM (n ¼ 6,784)† 0.3 (1.5 to 1.1) 3.2 (6.4 to 0.02) 0.81 (0.68 to 0.98) 0.89 (0.71 to 1.12)
p value‡ 0.66 0.05 0.03 0.38
Meta-analysis 0.83 (2.0 to 0.3) 4.9 (7.5 to 2.3) 0.75 (0.66 to 0.85) 0.80 (0.70 to 0.93)
p value‡ 0.16 2.4  104 1.1  105 2.5  103
Oral glucose tolerance test (OGTT) was performed at ARIC examination 4; IGT was defined as 2-h glucose $140 mg/dl. *Adjusted for age and sex. †For prevalent obesity,
FINRISK/DILGOM (Dietary, Lifestyle and Genetic Predictors of Obesity and Metabolic Syndrome), n ¼ 27,294. ‡Adjusted for age and sex, with additional adjustment for the first
5 (FINRISK/DILGOM) or 10 (ARIC) principal components as covariates to minimize confounding by ancestry.
Other abbreviations as in Tables 1 and 2.
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1770affected by alteration of the gene’s function, we
focused on long-term clinical outcomes using the
combined ARIC European- and African-American
samples. After a 25-year median follow-up, there
were 1,943 incident cases of DM, 1,556 incident HF
events, and 3,319 deaths. The N51S/A411T/H615Q
haplotype was significantly associated with a reduced
incidence of diagnosis of DM and initiation of
DM medications in unadjusted models (HR: 0.77
[95% CI: 0.66 to 0.89], p ¼ 3.8  104; HR: 0.72
[95% CI: 0.61 to 0.85], p ¼ 6.7  105, respectively)
and in age-, sex-, and principal component–adjusted
models (HR: 0.81 [95% CI: 0.69 to 0.94], p ¼ 0.006;
HR: 0.78 [95% CI: 0.66 to 0.92], p ¼ 0.004) (Online
Figure 1). This haplotype was also associated with
reduced risk of death or HF (HR: 0.80; 95% CI: 0.71 to
0.90; p ¼ 2.5  104) in the combined ARIC sample,
after adjustment for age, sex, and principal compo-
nents (p ¼ 8.9  104). This finding was also observed
when assessing the outcomes of HF and death sepa-
rately in both unadjusted models (HR: 0.71 [95% CI:
0.58 to 0.87], p ¼ 6.4  104; HR: 0.81 [95% CI: 0.71 to
0.93], p ¼ 0.0018) and adjusted models (HR: 0.74TABLE 4 Mendelian Randomization Analysis of 2-h Glucose
Lowering With Cardiometabolic Outcomes in Participants in the
ARIC Cohort, Instrumented by the Asn51Ser/Ala411Thr/His615Gln
SGLT1 Haplotype
OR or HR (95% CI) per
20-mg/dl Lower 2-h Glucose
Prevalent obesity 0.43 (0.23–0.63)
Incident diabetes 0.58 (0.35–0.81)
Incident heart failure 0.53 (0.24–0.83)
Death 0.66 (0.42–0.90)
HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.[95% CI: 0.60 to 0.91], p ¼ 0.0046; HR: 0.81 [95% CI:
0.71 to 0.94], p ¼ 0.0049).
We performed Mendelian randomization analysis,
instrumented by the SGLT1 haplotype, of 2-h glucose
values with cardiometabolic outcomes to estimate the
potential effect of pharmacological SGLT1 inhibition
on disease phenotypes. A decrease of 20 mg/dl in 2-h
glucose levels, instrumented by the SGLT1 haplotype,
was associated with lower odds of prevalent obesity
(OR: 0.43; 95% CI: 0.23 to 0.63) after adjustment for
age, sex, and principal components (Table 4). In long-
term outcomes, each decrease of 20 mg/dl in 2-h
glucose levels corresponded to a reduced incidence
of DM (HR: 0.58; 95% CI: 0.35 to 0.81), HF (HR: 0.53;
95% CI: 0.24 to 0.83), and death (HR: 0.66; 95% CI:
0.42 to 0.90) after adjustment for age, sex, and
principal components.
DISCUSSION
In European-American subjects and in a separate
replication sample of African-American subjects, in-
dividuals with NS mutations in SGLT1 had a lower risk
of IGT and obesity despite equivalent estimated
intake of total calories, sodium, and sugars at base-
line, and that this outcome was primarily driven by
the N51S/A411T/H615Q haplotype (Central
Illustration). We further found that individuals with
this haplotype had a lower incidence of DM, initiation
of DM therapies, death, and HF. These data suggest
that genetic variations in this gene influence the risk
of metabolic disease in relation to carbohydrate
intake and that selective inhibitors of SGLT1 may be
useful in prevention by reducing the burden of
metabolic disease and its cardiovascular disease
consequences.
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1771There are several lines of evidence which suggest
that the N51S/A411T/H615Q haplotype is likely to be
functional. The N51S, A411T, and H615Q variants have
been expressed in oocytes in a previous study and
were found to reduce uptake of glucose by 70% to
80% compared with controls, suggesting that these
variants, in isolation, have slightly reduced function
(1). Adding further support to the in vivo studies,
Combined Annotation Dependent Depletion scores
(18), a measure of pathogenicity, of all 3 variants are
high; these findings suggest that the altered amino
acid sequences are likely to have functional conse-
quence. Also similar to the in vivo findings, in our
work, we observed the strongest association of this
haplotype with reduced plasma glucose levels after
oral glucose exposure in 3 independent populations,
suggesting lower intestinal glucose uptake in haplo-
type carriers. Of interest, this haplotype includes 3
mutations in SGLT1, which may have originated from
a single founder. Data from 1,000 Genomes shows
that the highest frequency of the haplotype is carried
in participants from England and Scotland (12%),
followed by those of Indo-European ancestry (be-
tween 2% and 7%), South American ancestry
(approximately 1% to 2%), and lowest in those with
African heritage (0.008%). In a study of the evolu-
tionary history of genes encoding brush-border pro-
teins involved in carbohydrate digestion/absorption,
the SGLT1 A441T and H615Q variants were both
detected as positively selected sites in interspecies
analysis, with A441T being a modern-human-specific
site (19). These data support either a functional role
for these haplotype variants or suggest that they are
in strong linkage disequilibrium with a functional
variant. In analyses of a separate population-based
sample comprising individuals of European and spe-
cifically Finnish descent, we observed similarly sig-
nificant findings for postprandial glucose levels
and IGT.
To date, there have been no studies, to our
knowledge, comprehensively evaluating genetic
variation in SGLT1 with disease in a general
population–based cohort of any ethnic/racial compo-
sition. Previous research has focused on identifying
causal mutations in SGLT1 for GGM. This research has
established that mutations which result in complete
loss of function of SGLT1 lead to the extreme
phenotype of GGM: severe neonatal diarrhea causing
death from dehydration unless glucose and galactose
are removed from the diet. Similar to the presentation
in humans, Sglt1–/– mice develop GGM but are
healthy when given a diet absent of glucose and
galactose (20,21). When fed a Western-style diet,
Sglt1–/– mice display improved OGTT (20,21). Supportof the critical role of SGLT1 in maintaining body
weight comes from RS1 knockout (RS1[–/–]) mice. In
the absence of RS1, SGLT1 protein is overexpressed
7-fold, resulting in obesity, 30% increased body
weight, and 80% increased total body fat compared
with that of adult, wild-type mice (22). Although
complete loss of function of the protein causes GGM,
we would expect that mutations that cause even a
subtle change in function in the SGLT1 protein
that decreases absorption of intestinal glucose
could affect an individual’s propensity to develop
obesity and thereby reduce risk for DM. True caloric
consumption (calories absorbed) would not neces-
sarily reflect the number of calories that have been
eaten, and very small changes to the percentage of
total glucose eaten/total glucose absorbed could
explain a protection or susceptibility to obesity.
Adding further support that SGLT1 is important in
determining postprandial glucose levels in human
populations, a genome-wide association study of 1,5-
anhydroglucitol levels (a biomarker of hyperglycemic
excursions) identified significant linkage to SGLT1 in
2 independent European-American populations (23).
Inhibition of SGLT1 may also have secondary ef-
fects that could account for some of the observations
of the present study. In studies of humans and model
organisms, inhibiting SGLT1 has shown that
decreased glucose uptake in the small intestine re-
sults in increased luminal glucose in the more distal
gut and colon, stimulating a sustained increase in
circulating glucagon-like peptide (GLP)-1 and pep-
tide YY from L cells (24–26). This finding may be
mediated by bacterial fermentation of luminal
glucose to short-chain-fatty-acids that trigger GLP-1
secretion (25,27), leading to beneficial effects such
as decreased appetite and improved cardiac function
(28,29). Notably, GLP-1 and peptide YY are increased
with SGLT1 but not SGLT2-specific inhibition (25). In
addition, in our study, lowering of postprandial
glucose levels via SGLT1 was associated with
protection from HF. In murine models, cardiac
knockdown of SGLT1 in PRKAG2 cardiomyopathy
attenuated disease expression, suggesting a role of
SGLT1 in disease pathogenesis (30). Consistent with
this finding, transgenic overexpression of cardiac
SGLT1 was associated with myocardial hypertrophy
and left ventricular dysfunction that was reversible
by SGLT1 suppression. In another study, human
cardiac fibroblasts exposed to high glucose levels
increased expression of proteins involved in cardiac
fibrosis (i.e., matrix metalloproteinase-2) that was
reversed by phlorizin (a dual SGLT1 and SGLT2
inhibitor) but not by dapagliflozin (an SGLT2
inhibitor) (31). In addition to our data, these studies
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
SGLT1 absorbs glucose from the intestine, while both
SGLT2 and SGLT1 are involved in renal reabsorption.
Genetic mutations associated with loss of SGLT1
function are associated with lower post-prandial
glucose levels and avoidance of obesity.
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: SGLT2 inhibitors increase
urinary glucose excretion, reduce body weight, and
lower mortality and hospitalization for heart failure.
Potential adverse effects include urogenital infections
and euglycemic ketoacidosis.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to determine whether drugs that target
SGLT1 could reduce the incidence of diabetes and
heart failure and improve longevity in the general
population.
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1772provide support for the role of SGLT1 as a cardiac
sodium/glucose transporter that may be involved in
cardiomyopathy.
Marketed SGLT2 inhibitors for DM are a relatively
new class of drugs approved by the U.S. Food and
Drug Administration that vary in their selectivity for
the primarily renally expressed SGLT2, relative to the
primarily intestinally expressed SGLT1 (32). In addi-
tion to pharmacologically inhibiting renal glucose
reabsorption, SGLT2 inhibitors have shown the ben-
efits of decreased body weight and blood pressure,
and reduced mortality, cardiovascular events, and
hospitalization for incident HF, in 2 recently pub-
lished trials (EMPA-REG [Empagliflozin Cardiovascu-
lar Outcome Event Trial in Type 2 Diabetes Mellitus
Patients] and CANVAS [Canagliflozin Cardiovascular
Assessment Study]) (33,34). Unwanted side effects
of SGLT2 inhibition include a higher likelihood of
developing genital and urinary tract infections
(due to urinary excretion of glucose), osmotic
diuresis, and euglycemic ketoacidosis, all of which
would be expected to be diminished with increased
SGLT1 > SGLT2 inhibition. On a population level, the
data presented here indicate that more selective
SGLT1 inhibition may be of benefit in attenuating the
development of metabolic diseases, suggesting over-
all cardioprotection. Some of these effects may be
mediated through SGLT1-specific mechanisms such as
alteration of the microbiome and increased incretin
secretion, as described earlier. Although data on
SGLT1-specific inhibitors are lacking, initial data from
Phase II and III clinical trials of a dual SGLT1/SGLT2
inhibitor is consistent with our findings, with an ef-
fect size that was similar to the estimated effect size
in this Mendelian randomization analysis (35,36). Our
findings further suggest that there may be long-term,
protective effects of lowering intestinal glucose ab-
sorption via SGLT1 inhibition on cardiometabolic
outcomes.
STUDY LIMITATIONS. We did not extensively assess
the relationship of SGLT1 mutants in other population
studies; however, the ARIC is composed of partici-
pants from 4 distinct communities, and we have
replicated our findings in 2 diverse racial groups. The
association of the N51S/A411T/H615Q haplotype with
reduced DM, mortality, and HF should be considered
hypothesis generating and must be tested in addi-
tional prospective large-sized cohorts with similarly
longer term outcomes. Given the putative role of
SGLT1 in mediating diet-induced metabolic risk,
mutation-related effects on outcomes may vary based
on chronic dietary variation within or between pop-
ulations; thus, possible nutrient intake interactionswarrant further investigation in cohorts with detailed
dietary data in addition to prospective outcomes
data.
CONCLUSIONS
The SGLT1 N51S/A411T/H615Q haplotype was
associated with protection from postprandial hyper-
glycemia and obesity in European- and African-
American subjects from 4 U.S. communities and 2
European cohorts from Finland. These data provide
support that reduction of postprandial glucose levels
via SGLT1 inhibition may be associated with reduced
incidence of DM, HF, and/or mortality in certain
populations at risk. These data argue for further
research into the role of natural variation in SLGT1 in
metabolic disease and suggest that more selective
ways to inhibit SGLT1 may lead to therapies that
reduce the deleterious effects of Western-style diets.
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